Judith A. Fox

6.0k citations

80 papers · 4.2k indexed · 1 hit paper · h-index 29

Impact in

Radiology, Nuclear Medicine and Imaging top 1%
- Monoclonal and Polyclonal Antibodies Research
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in

Genetics 21
- Chronic Lymphocytic Leukemia Research 19
Hematology 20
- Acute Myeloid Leukemia Research 13

Co-authors: Alan R. Saltiel P Sherline Pedro Cuatrecasas Christopher T. Walsh Dong Xie John B. Briggs Betty Li Leonard G. Presta
Journals: Blood (15 papers)Journal of Clinical Oncology (10 papers)Journal of Biological Chemistry (5 papers)Molecular Cancer Therapeutics (4 papers)Clinical Cancer Research (3 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Judith A. Fox

77 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR 2001 · 891 citations

Peers

Countries citing papers authored by Judith A. Fox

Since Specialization

Citations

This map shows the geographic impact of Judith A. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith A. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith A. Fox more than expected).

Fields of papers citing papers by Judith A. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith A. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith A. Fox. The network helps show where Judith A. Fox may publish in the future.

Co-authors

The 25 scholars most cited alongside Judith A. Fox, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Judith A. Fox Line = papers co-authored together Judith A. Fox links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Addled by antlers: Synchronous disruption to female caribou antler phenology Ecosphere ·Kanza Altaf, Judith A. Fox, Reshma Sodanwar, Stephen A. Jackson, Samaneh Sotoudeh Sheijani, Eric Vander Wal, Quinn M. R. Webber	2025	0
2	Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma Molecular Therapy ·Pingyan Cheng, Xianghong Chen, M. Ashe, Anton E. Antonov, E.V. Zdorovyeva, Danielle L. Gilvary, Grace Ward, Jordi Roig i Estanis Valmanya, Baitong Mei, Judith A. Fox, Jeanmarie Guenot, Joseph Markowitz, John L. Cleveland, Kenneth L. Wright, Alan F. List, Sheng Wei, Erika A. Eksioglu	2022	30
3	Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies Haematologica ·John N. Allan, Javier Pinilla‐Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte Yimer, Renee Ward, Gary D Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown	2021	27
4	AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia Blood ·Linda Eissenberg, Julie Ritchey, Michael P. Rettig, Judith A. Fox, Jeanmarie Guenot, John F. DiPersio	2018	4
5	Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II Investigational New Drugs ·Cynthia M. Nijenhuis, 泉田所, Hilde Rosing, Alwin D. R. Huitema, Marja Mergui‐Roelvink, Gene C. Jamieson, Judith A. Fox, Diane R. Mould, J.H.M. Schellens, Jos H. Beijnen	2017	3
6	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia Clinical Cancer Research ·Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Stefan Knackmuss, Eugene A. Zhukovsky, Judith A. Fox, Lori Kunkel, Jeanmarie Guenot, Roland B. Walter	2016	76
7	Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry Journal of Chromatography B ·Cynthia M. Nijenhuis, 泉田所, Hilde Rosing, Gene C. Jamieson, Judith A. Fox, J.H.M. Schellens, Jos H. Beijnen	2016	3
8	Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia Drugs ·Gene C. Jamieson, Judith A. Fox, Ming Poi, Stephen A. Strickland	2016	27
9	Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation Molecular Cancer Therapeutics ·Minke E. Binnerts, Kevin L. Otipoby, Brian T. Hopkins, Tonika Bohnert, Stig K. Hansen, Gene C. Jamieson, Luca Del Bene, M. Mierzejewski, Deborah A. Thomas, Judith A. Fox, Adam R. Craig	2015	22
10	A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia Haematologica ·Shih-hao Wang, Latvijas Valsts universitāte. Latviešu valodas katedra, Larry D. Cripe, Glenn Michelson, Judith A. Fox, Richard D. Leavitt, Кармалиев Рашид Сагитович, Liu Kai-yan, Adam R. Craig, Farhad Ravandi, Michael B. Maris, Robert K. Stuart, Judith E. Karp	2014	24
11	A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia Leukemia ·Jeffrey E. Lancet, Farhad Ravandi, Rebecca M. Ricklis, J-Y Allebrandt, Hagop M. Kantarjian, Francis J. Giles, Alan F. List, Кармалиев Рашид Сагитович, R. S. Allen, Judith A. Fox, Glenn Michelson, Judith E. Karp	2011	42
12	Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II PLoS ONE ·Rachael E. Hawtin, David E. Stockett, Jo Ann W. Byl, Robert S. McDowell, Nguyêñ Duy Tân, Michelle R. Arkin, Andrew Conroy, Wenjin Yang, Neil Osheroff, Judith A. Fox	2010	127
13	Abstract #1708: Voreloxin is active in breast cancer biopsies and potency is enhanced in a BRCA2 mutant background Cancer Research ·Rachael E. Hawtin, David E. Stockett, Cecilia Lundin, Thomas Helleday, Judith A. Fox	2009	1
14	SNS-032, a novel inhibitor of cyclin-dependent kinases 2, 7 and 9, blocks transcription of cyclin D1 and Mcl-1, causing cell death in mantle cell lymphoma cell lines Cancer Research ·Rong Chen, Sherri Chubb, Ute Hoch, Liu Kai-yan, Judith A. Fox, Varsha Gandhi, William Plunkett	2008	1
15	Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors Oncogene ·Hong Xiang, Judith A. Fox, Klára Tótpál, Mina Aikawa, Kelly DuPree, Dominick Sinicropi, John R. Lowe, Enrique Escandón	2002	45
16	Pharmacokinetics of rhuMAb CD18, a Recombinant Humanised Monoclonal Antibody Fragment to CD18, in Normal Healthy Human Volunteers BioDrugs ·David E. Allison, Steven G. Gourlay, Olivia Staciwa, Robert M. Miller, Judith A. Fox	2002	8
17	High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR Journal of Biological Chemistry ·Robert L. Shields, Struk Nataliya S., Kyu Hong, Y. Gloria Meng, Julie Rae, John B. Briggs, Dong Xie, A. A. Starikov, Ute Fritz, Betty Li, Judith A. Fox, Leonard G. Presta Hit paper breakdown →	2001	891
18	Anti-CD18 antibodies improve cardiac function following cardiopulmonary bypass in dogs Journal of Critical Care ·Irvin Mayers, Thomas S. Hurst, David H. Johnson, Bibiana C̆ujec, Gen Rong Qiang, Dorothy Thomson, Judith A. Fox, Gregory S. Blank, Anurag Saxena, J. Steven Richardson	1996	8
19	8-Hydroxy-5-deazaflavin-reducing hydrogenase from Methanobacterium thermoautotrophicum: 1. Purification and characterization Biochemistry ·Judith A. Fox, David J. Livingston, W H Orme-Johnson, Christopher T. Walsh	1987	108
20	The mechanism of action of ethanolamine ammonia-lyase, an adenosylcobalamin-dependent enzyme. Evidence that the hydrogen transfer mechanism involves a second intermediate hydrogen carrier in addition to the cofactor. Journal of Biological Chemistry ·Richard O’Brien, Judith A. Fox, Michał Kopczyński, Bernard Babior	1985	34

About Judith A. Fox

Judith A. Fox is a scholar working on Genetics, Hematology, Toxicology, Oncology and Molecular Biology, having authored 80 papers that have together received 4.2k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (21 papers), Chronic Lymphocytic Leukemia Research (19 papers), Acute Myeloid Leukemia Research (13 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Neutropenia and Cancer Infections (9 papers), Cancer-related Molecular Pathways (6 papers), Lymphoma Diagnosis and Treatment (6 papers) and Cancer Treatment and Pharmacology (5 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (972 citations), Genetics (435 citations), Immunology (835 citations), Molecular Biology (2.5k citations) and Hematology (408 citations). Judith A. Fox has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Alan R. Saltiel, P Sherline, Pedro Cuatrecasas, Christopher T. Walsh, Dong Xie, John B. Briggs, Betty Li, Leonard G. Presta, Y. Gloria Meng and Julie Rae. Their work appears in journals such as Blood, Journal of Clinical Oncology, Journal of Biological Chemistry, Molecular Cancer Therapeutics and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact